The healthcare landscape in England witnesses a novel approach as the National Institute for Health and Care Excellence (NICE) introduces Early Value Assessments (EVAs). This initiative aims to fast-track promising health technologies, potentially aligning with the National Health Service’s (NHS) Long Term Plan while addressing unmet health needs. Such assessments, however, present a dearth of published analysis regarding the methodologies employed across different EVA Reports, leaving a significant gap in understanding their unique or shared approaches.
Methods and Approach
A rigorous rapid scoping review documented all EVAs accessible on the NICE website up until July 23, 2024. The review process proceeded with one reviewer initially screening records for eligibility, followed by a check from another reviewer for confirmation. Teams of two reviewers independently extracted data concerning methodologies using a pre-designed form, ensuring accuracy through subsequent validation. This data found representation in both graphical and tabular formats, complemented by narrative summaries for better comprehension.
Findings and Presentation
The analysis encompassed seventeen reports from sixteen EVAs. Notably, five reports omitted details on the number of reviewers involved in the screening, while another five lacked clarity on data extraction methods. The EVAs also varied in their analytical plans, with five opting for meta-analyses, nine choosing narrative syntheses, and seven considering narrative summaries. Additionally, eleven decision models were put forth, showcasing diverse cost-analysis techniques, including cost-utility analyses, cost-effectiveness analyses, cost-consequence analyses, and comparisons.
Several key inferences emerge from this review:
–
EVAs offer a dynamic platform for innovative healthcare technology assessments.
–
Implementing transparency remains essential for methodological consistency.
–
Enhanced collaboration among stakeholders could drive better health outcomes.
NICE’s initiative in promoting early value assessments marks a significant stride in integrating novel health technologies within the NHS framework. Moving forward, it becomes imperative that EVA Reports strengthen the transparency of their methodologies to foster trust and sustain effectiveness. Embracing innovation and engaging stakeholders, including patients and clinicians alongside companies and NICE itself, could drive methodological advancements, ensuring that these promising technologies fulfill their potential in practice. Through careful refinement and inclusive practices, EVAs could set a benchmark for health technology assessments on a global scale, offering insights for nations exploring similar paths.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
